PGEN shows severe financial deterioration with net losses doubling to $251M, interest expense exploding 1,296%, and stockholders' equity declining 46% while transitioning from going concern warnings to dependence on commercial success of newly named drug Papzimeos.
The dramatic shift from going concern language to commercial dependence messaging, combined with a massive 60M share increase, suggests PGEN may have secured financing or partnership tied to their lead asset (formerly PRGN-2012, now Papzimeos). However, the explosion in interest expense and liabilities indicates this capital came at a very high cost, creating substantial financial risk.
PGEN's financials show severe stress with net losses doubling to $251M driven by 1,296% surge in interest expense to $8.5M and 70% increase in SG&A expenses, while R&D spending declined 22%. The balance sheet deteriorated significantly with total liabilities jumping 71% to $135M, stockholders' equity falling 46% to $21M, and operating cash burn worsening 29% to $88M. The combination of exploding debt service costs, shrinking equity cushion, and worsening cash burn creates a precarious financial position despite the apparent influx of capital suggested by the 60M share increase.
Interest expense surged 1296.1% — significant debt increase or rising rates materially impacting earnings.
Receivables surged 322.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Net income declined 98.6% — review whether driven by operations, interest costs, or non-recurring items.
Capex reduced 76.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Current liabilities surged 73.4% — significant near-term obligations; verify ability to meet short-term debt.
Liabilities grew 71.4% — significant increase in debt or obligations, assess impact on financial flexibility.
SG&A up 69.8% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
R&D spending cut 22.1% — could signal cost discipline or concerning reduction in innovation investment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →